Inibitori della beta-adrenergica dopo infarto miocardico con eiezione ventricolare sinistra preservata o leggermente ridotta: fragilità delle evidenze contemporanee.

BACKGROUND: β-Blockers have been traditionally prescribed after acute myocardial infarction (MI), but contemporary evidence in patients with preserved or mildly reduced left ventricular ejection fraction (LVEF ≥40%) have not provided consistent results. We assessed the robustness of the evidence for the efficacy of β-blocker therapy in this population using contemporary randomized controlled trials (RCTs) and pooled analyses. METHODS: We systematically searched PubMed, Scopus, and Embase through August 1, 2025, for phase 3-4 RCTs evaluating β-blockers in patients with LVEF ≥40% during index MI hospitalization. Primary outcomes included robustness of each trial's primary endpoint; secondary